Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.47 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22139856 | 0.81 | HPGD (0.46) | ERCC1FEN1ERCC4HPGDKDM4C | |
| SCHEMBL26672966 | 0.81 | HPGD (0.46) | ERCC1FEN1ERCC4HPGDNPSR1 | |
| SCHEMBL12138839 | 0.81 | HPGD (0.46) | ERCC1FEN1ERCC4HPGDNPSR1 | |
| SCHEMBL2146034 | 0.79 | NPSR1 (0.46) | ERCC1FEN1ERCC4HPGDKDM4C | |
| SCHEMBL52380 | 0.77 | CYP2C19 (0.48) | ERCC1FEN1ERCC4RNASEH1KDM4E | |
| SCHEMBL10552507 | 0.76 | NPSR1 (0.46) | HPGDKDM4CNPSR1KDM4EALDH1A1 | |
| SCHEMBL5433655 | 0.76 | NPSR1 (0.46) | HPGDKDM4CNPSR1KDM4EALDH1A1 | |
| SCHEMBL460243 | 0.76 | GDA (0.42) | ERCC1FEN1ERCC4KDM4EALDH1A1 | |
| SCHEMBL1081091 | 0.76 | LMNA (0.54) | HPGDKDM4CNPSR1KDM4EALDH1A1 | |
| SCHEMBL24596263 | 0.74 | NPSR1 (0.45) | HPGDKDM4CNPSR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8563562-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2013-10-22 | — | — | US | disclosed |
| US-8431581-B2 | Imidazopyrimidines and uses thereof | AVEXA LIMITED (AU) | 2013-04-30 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2013-03-07 | — | — | US | disclosed |
| US-8318732-B2 | Compounds having antiviral properties | AVEXA LIMITED (AU) | 2012-11-27 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-8207334-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-06-26 | — | — | US | disclosed |
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | AVEXA LIMITED (AU) | 2011-02-17 | — | — | US | disclosed |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-02-03 | — | — | US | disclosed |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-01-13 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039842-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | ERCC1 3108/4885FEN1 610/4885ERCC4 1031/4885 |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | ERCC1 3335/4885FEN1 976/4885ERCC4 1795/4885 |
| US-20110028487-A1 | IMIDAZOPYRIMIDINES AND USES THEREOF | TPMT, DPYD, IMPDH1 | ERCC1 3096/4885FEN1 725/4885ERCC4 897/4885 |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | TPMT, CYP2C19, CYP3A5 | ERCC1 4702/4885FEN1 2118/4885ERCC4 3387/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | ERCC1 3335/4885FEN1 976/4885ERCC4 1795/4885 |
| US-20110009366-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | ERCC1 3335/4885FEN1 976/4885ERCC4 1795/4885 |
| US-20130059865-A1 | COMPOUNDS HAVING ANTIVIRAL PROPERTIES | ZC3HAV1, ACE, EIF2AK2 | ERCC1 3108/4885FEN1 610/4885ERCC4 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.